The therapeutic effect of parlodel in the polycystic ovary syndrome

Parlodel (2.5-50 mg/day) has been given for 1 to 7 days to 33 patients with the polycystic ovary syndrome (POS). The ovulatory menstrual cycle returned in 10 (30%) patients and 4 of them conceived. Pretreatment cycle disturbance persisted in 6 (18%) patients. Parlodel reduced mid-follicular mean blo...

Full description

Saved in:
Bibliographic Details
Published inAkusherstvo i ginekologii͡a no. 9; p. 61
Main Authors Soboleva, E L, Komarov, E K, Potin, V V, Svechnikova, F A
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.09.1990
Subjects
Adolescent
Adult
Bromocriptine - therapeutic use
Drug Evaluation
Estradiol - blood
Female
Gonadotropins, Pituitary - blood
Humans
Menstruation Disturbances - blood
Menstruation Disturbances - drug therapy
Menstruation Disturbances - etiology
Polycystic Ovary Syndrome - blood
Polycystic Ovary Syndrome - complications
Polycystic Ovary Syndrome - drug therapy
Progesterone - blood
Radioimmunoassay
Testosterone - blood
Online AccessGet more information

Cover

More Information
Summary:Parlodel (2.5-50 mg/day) has been given for 1 to 7 days to 33 patients with the polycystic ovary syndrome (POS). The ovulatory menstrual cycle returned in 10 (30%) patients and 4 of them conceived. Pretreatment cycle disturbance persisted in 6 (18%) patients. Parlodel reduced mid-follicular mean blood LH levels to values of normal women. Some decrease in blood testosterone levels occurred only in the second phase of the cycle. Estradiol test in 6 patients showed normal positive and negative feedbacks in the hypothalamic-pituitary-ovarian axis. Parlodel treatment reduced basal and estradiol stimulated pituitary gonadotropin secretion. It is suggested that parlodel may be used in ovulation induction in a proportion of POS patients.
ISSN:0300-9092